Rain Therapeutics Announces Late-Breaker Oral Presentation at the 32nd EORTC-NCI-AACR Virtual Symposium
October 14, 2020 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
Rain Therapeutics Announces Appointment of Robert Doebele, MD, PhD as Executive Vice President and Chief Scientific Officer
September 15, 2020 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
Rain Therapeutics to Present at Citi’s 15th Annual BioPharma Virtual Conference
September 03, 2020 16:00 ET
|
Rain Therapeutics
NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
Rain Therapeutics Closes $63 Million Series B Financing
September 03, 2020 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, has closed a...
Rain Therapeutics Announces Exclusive License to the Clinical-Stage MDM2 Inhibitor, DS-3032 (Milademetan) from Daiichi Sankyo
September 02, 2020 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer,...
Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway
August 25, 2020 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today...
Rain Therapeutics to Present at the UBS Global Healthcare Conference
May 13, 2019 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients...
Rain Therapeutics Presents Preclinical Data on Lead Candidate Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting
April 03, 2019 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
Rain Therapeutics Presents Preclinical Activity of Tarloxotinib in NRG1 Fusion Cancers at the Annual American Association for Cancer Research (AACR) Meeting
April 02, 2019 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...
Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations
March 19, 2019 08:00 ET
|
Rain Therapeutics
NEWARK, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for...